PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24057416-9 2013 Trastuzumab in combination with cisplatin and a fluoropyrimidine is an effective regimen for patients with HER2-positive advanced gastric cancer, has acceptable tolerability and represents an important advance in the treatment of gastric cancer. 2-fluoropyrimidine 48-64 erb-b2 receptor tyrosine kinase 2 Homo sapiens 107-111 26359224-4 2015 For human epidermal growth factor receptors 2 (HER2) negative cancer, standard treatments are combinations of fluoropyrimidine and platinum with or without epirubicin or docetaxel in first-line therapy. 2-fluoropyrimidine 110-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 47-51 26359224-6 2015 For HER2 positive cancer, standard treatments are combinations of fluoropyrimidine and cisplatin with trastuzumab. 2-fluoropyrimidine 66-82 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-8 24749947-3 2014 This trial showed the addition of trastuzumab to fluoropyrimidine/platinum chemotherapy as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive GC that resulted in an overall survival (OS) benefit. 2-fluoropyrimidine 49-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 119-159 21673877-2 2011 In the ToGA trial, the addition of the monoclonal antibody trastuzumab to a standard regimen of cisplatin and fluoropyrimidine resulted in a clinically and statistically significant benefit in terms of response rate, median progression-free survival, and median overall survival in HER2-positive patients. 2-fluoropyrimidine 110-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 282-286 23680713-5 2013 The anti-HER-2 antibody, trastuzumab, when added to a chemotherapeutic regimen combining a fluoropyrimidine and platinum, provides a survival benefit for those patients with HER-2 overexpression and/or amplification. 2-fluoropyrimidine 91-107 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-14 23197882-4 2012 In patients with advanced or metastatic gastric/GOJ cancer systemic chemotherapy with fluoropyrimidine/platinum-based regimens (+/-human epidermal growth factor receptor-2 antibody) is the mainstay of treatment. 2-fluoropyrimidine 86-102 erb-b2 receptor tyrosine kinase 2 Homo sapiens 137-171 23007148-1 2012 BACKGROUND: Trastuzumab in combination with doublet chemotherapy (cisplatin and fluoropyrimidine) is a standard treatment for patients with HER2-positive advanced gastric cancer. 2-fluoropyrimidine 80-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 140-144 17611667-0 2007 Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. 2-fluoropyrimidine 72-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-136 21129604-7 2010 Based on these results trastuzumab combined with a cisplatin and fluoropyrimidine regimen appear the new reference treatment for HER-2 positive metastatic gastric cancer. 2-fluoropyrimidine 65-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-134 12680178-0 2003 Implication of HER-2/neu overexpression for the efficacy of oral fluoropyrimidine-based adjuvant chemotherapy in the patients with estrogen receptor negative breast cancer after surgery. 2-fluoropyrimidine 65-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 15-24 12680178-2 2003 The present study retrospectively assessed the effects of HER-2/neu overexpression on the efficacy of oral fluoropyrimidine-based ACT and AET after breast cancer surgery. 2-fluoropyrimidine 107-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 58-67 34420059-0 2022 Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. 2-fluoropyrimidine 122-138 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-71 34420059-1 2022 BACKGROUND: We aimed to evaluate the prognostic value of natural killer (NK) cell activity for patients with HER2 + advanced gastric cancer (AGC) treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. 2-fluoropyrimidine 170-186 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-113 33042632-2 2020 The ToGA study showed that trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced GC (AGC). 2-fluoropyrimidine 59-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-180 32970266-2 2021 METHODS: The study includes patients with HER2(-) AGC treated with platin and fluoropyrimidine (PF) or with DPF in first line. 2-fluoropyrimidine 78-94 erb-b2 receptor tyrosine kinase 2 Homo sapiens 42-46 33042632-2 2020 The ToGA study showed that trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced GC (AGC). 2-fluoropyrimidine 59-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 182-186 31851321-3 2020 METHODS: HER2-HER3 dimerization was quantified by "FLIM Histology" in primary tumor samples from 550 COIN trial patients receiving oxaliplatin and fluoropyrimidine chemotherapy +/-cetuximab. 2-fluoropyrimidine 147-163 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-13 31251346-13 2020 Anthracycline-based triplets and fluoropyrimidine-based doublets without cisplatin may be preferable first-line treatment options regarding HRQoL for HER2-negative disease. 2-fluoropyrimidine 33-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-154 29090377-1 2018 BACKGROUND: Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. 2-fluoropyrimidine 29-45 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 30088161-1 2019 BACKGROUND: Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma; however, there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. 2-fluoropyrimidine 43-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 100-104 28936560-2 2018 The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. 2-fluoropyrimidine 29-45 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-145 28936560-2 2018 The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. 2-fluoropyrimidine 29-45 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-151 26254345-6 2015 Regimens containing fluoropyrimidine and platinum agents, in combination with trastuzumab in patients with overexpression of human epidermal growth factor receptor 2 (HER2), are recommended as the first-line treatment. 2-fluoropyrimidine 20-36 erb-b2 receptor tyrosine kinase 2 Homo sapiens 167-171 27599830-1 2017 BACKGROUND: Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). 2-fluoropyrimidine 97-113 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-137